Clinical Trials
103 trialsNCT05712356 2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Terminated
NCT05567835 2026-04-09
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT06739252 2026-01-28
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
Phase 2 Terminated
NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
NCT04854499 2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2 Terminated
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT04141995 2025-08-07
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
University of Nebraska
Phase 2 Terminated
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT03387592 2025-03-10
SENECA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT03822936 2025-02-13
PIOPPO
CNAO National Center of Oncological Hadrontherapy
Phase 2 Terminated
NCT03117972 2025-02-05
CLavSyn
Centre Hospitalier Universitaire de Besancon
Phase 2 Terminated
NCT03736720 2025-01-30
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Roswell Park Cancer Institute
Phase 2 Terminated
NCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04937738 2024-11-06
PECORINO
Ukrainian Society of Clinical Oncology
Phase 2 Terminated
NCT05009953 2024-07-11
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
NCT00601198 2023-08-01
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
University of Cincinnati
Phase 2 Terminated
NCT00551759 2023-07-03
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT03099265 2022-10-27
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Yale University
Phase 2 Terminated
NCT00573131 2022-06-22
Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Boston Scientific Corporation
Phase 2 Terminated
NCT03099486 2022-02-07
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Fox Chase Cancer Center
Phase 2 Terminated
NCT00003777 2022-01-26
Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT03050814 2021-12-20
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02319304 2021-11-04
GCC 1314
University of Maryland, Baltimore
Phase 2 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT00005944 2021-02-17
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
UNICANCER
Phase 2 Terminated
NCT03368859 2021-02-09
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
Phase 2 Terminated
NCT00006472 2020-08-18
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT02405585 2020-05-28
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Lumos Pharma
Phase 2 Terminated
NCT00602329 2020-04-28
MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT02141295 2020-03-25
McCAVE
Hoffmann-La Roche
Phase 2 Terminated
NCT00539617 2020-03-23
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
University of California, San Francisco
Phase 2 Terminated
NCT00541112 2020-02-11
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
UNICANCER
Phase 2 Terminated
NCT00955240 2020-02-11
Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
UNICANCER
Phase 2 Terminated
NCT00580073 2019-12-13
Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
University of Wisconsin, Madison
Phase 2 Terminated
NCT01479465 2019-04-17
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Gilead Sciences
Phase 2 Terminated
NCT01372202 2019-01-25
J10130
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00611858 2019-01-08
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02508077 2018-08-16
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT01608464 2018-08-10
Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer
King Faisal Specialist Hospital & Research Center
Phase 2 Terminated
NCT02241551 2018-07-26
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT02345460 2018-07-13
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00646659 2018-07-09
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01359007 2018-03-09
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
University of Oklahoma
Phase 2 Terminated
NCT00832299 2018-03-01
Neo-Adjuvant FOLFOX for Rectal Carcinoma
Beth Israel Medical Center
Phase 2 Terminated